Teva’s Cinqair gets FDA approval

SILVER SPRING, Md. — The Food and Drug Administration announced Tuesday that it had approved Teva Pharmaceuticals’ Cinqair (reslizumab). The drug is indicated as maintenance treatment for severe asthma in patients over age 18 alongside other medications. 

 

The infusion drug is meant to be administered every four weeks at a facility that can manage anaphylazis, as potential side effects include life-threatening allergic reactions. It reduces severe asthma attacks by working to reduce levels of a type of white blood cell that contributes to asthma’s development.